Treatment of recalcitrant atopic dermatitis with omalizumab

Lane, Joshua E.; Cheyney, Jason M.; Lane, Tanda N.; Kent, David; Cohen, David J.

doi:10.1016/j.jaad.2005.09.030

Cited by 168 publications

(112 citation statements)

References 17 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…As mentioned above, it takes 3 months to see an effect with omalizumab. In a similar context, the mean serum IgE levels of the unsuccessful patients were much higher than those in the successful patients 6,9,12 . If the dose of omalizumab is insufficient, then the drug does not thoroughly block all the IgE.…”

Section: Discussionmentioning

confidence: 82%

“…In the unsuccessful cases, although the patients all are adults, omalizumab was administrated at 450 mg subcutaneously every other week for 4 months 6 . However, for the successful cases, most of the patients were children and the dosing was similar to that of the patients of the unsuccessful cases 9,12 .…”

Section: Discussionmentioning

confidence: 85%

“…Some dermatologists have been tried to treat AD patients with omalizumab, and the majority of them were successful in treating AD with omalizumab 9,12 . On the other hand, a few AD patients failed when being treated with omalizumab 6 .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Recalcitrant Atopic Dermatitis Treated with Omalizumab

Park

Choi

et al. 2010

Ann Dermatol

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic cutaneous inflammatory disease. Various categories of therapeutic medications are used for treating AD. Omalizumab is a monoclonal anti-IgE antibody that binds to IgE molecules at the high-affinity receptor (FcεRI) binding site. Therefore, omalizumab can be used as a potential new systemic treatment agent for recalcitrant AD patients with elevated IgE levels. A 34-year-old man had been treated for AD with several topical and oral agents. However, he was refractory to these therapies and his serum IgE levels were very high. We treated him with omalizumab. After 8 months of the treatment, his symptoms were notably improved and the SCORAD index was decreased. Thus, we report on the first case of recalcitrant AD that was successfully treated with omalizumab in Korea. (Ann Dermatol 22(3) 349∼352,

show abstract

Section: Discussionmentioning

confidence: 82%

Section: Discussionmentioning

confidence: 85%

See 1 more Smart Citation

Recalcitrant Atopic Dermatitis Treated with Omalizumab

Park

Choi

et al. 2010

Ann Dermatol

View full text Add to dashboard Cite

show abstract

“…It binds free IgE but not IgE bound to FcεRI on masts cells, so in this way it sequesters free IgE without activating bound IgE and causing mast cell degranulation (Presta et al, 1993). Omalizumab has been approved by the FDA for use in severe recalcitrant asthma (Strunk & Bloomberg, 2006) and has been investigated for severe cases of atopic dermatitis with positive results (Lane et al, 2006 …”

Section: Biological Agents -Monoclonal Antibodiesmentioning

confidence: 99%

Natural Products and Dermatological Hypersensitivity Diseases

MacDonald¹,

Kulka²

2012

Allergic Diseases - Highlights in the Clinic, Mechanisms and Treatment

View full text Add to dashboard Cite

“…There are a few case reports of improvement in AD with omalizumab. 162 However given the cost and lack of controlled trials it currently can not be recommended for treatment.…”

Section: Anti-ige Therapymentioning

confidence: 99%

Clinical correlations of recent developments in the pathogenesis of atopic dermatitis

Sehra

Tuana

Holbreich

et al. 2008

An. Bras. Dermatol.

View full text Add to dashboard Cite

Atopic dermatitis is a chronic inflammatory skin disease with a steadily increasing prevalence affecting 10-20 % of infants and 1-3% of adults globally. It is often the first clinical manifestation of atopic disease preceding asthma and allergic rhinitis. Probably half of the children with atopic dermatitis develop some other form of atopic disease later in life. The pathogenesis involves a complex interplay of factors including genetic predisposition due to altered immune or skin barrier function, interactions with the environment such as food and allergen exposures, and infectious triggers of inflammation. In this review, we summarize the recent advances in understanding the contribution of different factors in the pathophysiology of atopic dermatitis and how insights provide new therapeutic potential for its treatment. Keywords: Asthma; Atopic Dermatitis, Eczema; Eosinophils; Genetics; Immunoglobulin E; Keratinocytes; Rhinitis, T-Lymphocytes Resumo: A dermatite atópica é uma doença cutânea inflamatória crônica cuja prevalência tem aumentado de forma constante, afetando 10-20% dos lactentes e 1-3% dos adultos em todo o mundo. Ela é freqüentemente a primeira manifestação clínica de doença atópica, precedendo a asma e a rinite alérgica. Provavelmente metade das crianças com dermatite atópica desenvolvem alguma

show abstract

Treatment of recalcitrant atopic dermatitis with omalizumab

Cited by 168 publications

References 17 publications

Recalcitrant Atopic Dermatitis Treated with Omalizumab

Recalcitrant Atopic Dermatitis Treated with Omalizumab

Natural Products and Dermatological Hypersensitivity Diseases

Clinical correlations of recent developments in the pathogenesis of atopic dermatitis

Contact Info

Product

Resources

About